MANNKIND CORP Payments of Debt Issuance Costs
MANNKIND CORP (MNKD) reported Payments of Debt Issuance Costs of $7.27 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2024-02-27
- MANNKIND CORP payments of debt issuance costs for the quarter ending 2021-12-31 was $0.00.
- MANNKIND CORP payments of debt issuance costs for the quarter ending 2021-09-30 was $0.00.
- MANNKIND CORP payments of debt issuance costs for the quarter ending 2021-06-30 was $0.00.
- MANNKIND CORP payments of debt issuance costs for the quarter ending 2021-03-31 was $7.27M.
- MANNKIND CORP payments of debt issuance costs for fiscal 2021 was $7.27M.
- MANNKIND CORP payments of debt issuance costs for fiscal 2015 was $831.00K.
- MANNKIND CORP payments of debt issuance costs for fiscal 2013 was $598.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 271 month | Payments of Debt Issuance Costs 275 month | Payments of Debt Issuance Costs 277 month | Payments of Debt Issuance Costs 280 month | Payments of Debt Issuance Costs 283 month |
|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $7.27M 10-K · filed 2024-02-27 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $7.27M 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $7.27M 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | $7.27M 10-Q · filed 2022-05-05 | ||||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $831.00K 10-K · filed 2018-02-27 | |||||||
| 2015-09-30 | $831.00K 10-Q · filed 2016-11-09 | ||||||||
| 2014-09-30 | $598.00K 10-Q · filed 2014-11-10 | ||||||||
| 2014-06-30 | $598.00K 10-Q · filed 2014-08-11 | ||||||||
| 2014-03-31 | $598.00K 10-Q · filed 2014-05-12 | ||||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $598.00K 10-K · filed 2016-03-15 | $598.00K 10-K · filed 2014-03-03 | ||||||
| 2013-09-30 | $598.00K 10-Q · filed 2014-11-10 | $598.00K 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |